相关实验视频

Updated: May 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

基于器官的单细胞测序揭示了在胃癌中多塞塔塞尔治疗期间的血统演变

Dejun Yang¹, Xin Zhang², Zunqi Hu¹

¹Department of Gastrointestinal Surgery, Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University, Huangpu District, No. 415 Fengyang Road, Shanghai, 200003, China.

|March 21, 2025

概括

这项研究确定了关键基因 (FOS,IFI27,PTTG1IP) 驱动胃癌中多塞塔塞尔耐药性. 针对这些基因可以恢复药物敏感性,并改善患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

多西素耐药性是胃癌治疗中的一个重大障碍.
了解抵抗的细胞和分子机制对于开发有效疗法至关重要.

研究的目的:

为了研究与胃癌中多塞素耐药性相关的细胞和分子变化.
为了确定参与多塞素耐药性的关键基因.
评估针对这些与耐药性相关的基因的治疗潜力.

主要方法:

建立对多塞塔塞尔敏感和耐药的胃癌器官.
单细胞RNA测序以分析细胞和分子变化.
伪时间轨迹分析,以了解细胞分化.
在细胞系和有机体中进行基因淘汰实验.
在体内研究以评估瘤生长.

主要成果:

耐药胃癌类器官体显示分泌,免疫化学和过渡细胞种群的增加.
在耐药器官和患者样本中观察到FOS,IFI27和PTTG1IP的升级.
在终端分化阶段发现了耐药细胞.
通过抑制FOS,IFI27和PTTG1IP,通过调节ROS,自和亡,恢复了多塞素的敏感性.
在活体中,这些基因的沉默降低了在多塞塔克塞尔治疗下瘤的生长.

结论:

FOS,IFI27和PTTG1IP是胃癌中多塞塔克塞尔耐药性的关键驱动因素.
准FOS,IFI27和PTTG1IP是一个有希望的战略,以克服多塞素耐药性.
这种方法可以改善胃癌患者的治疗结果.

关键词:

化学抗药性化学抗药性是一种抗药性.胃癌胃癌是指胃癌.有机器人机器人机器人机器人一个单细胞RNA-seqq.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...